Kenai Therapeutics completes enrollment for Parkinson’s cell therapy trial
Kenai Therapeutics has completed enrollment in the REPLACE Phase 1b/2a clinical trial of RNDP-001 for moderate to moderate-severe idiopathic Parkinson’s disease, the company announced on 7 July 2026, in San Diego. RNDP-001 is an off-the-shelf, allogeneic neuron replacement cell therapy designe
<p>Kenai Therapeutics has completed enrollment in the REPLACE Phase 1b/2a clinical trial of RNDP-001 for moderate to moderate-severe idiopathic Parkinson’s disease, the company announced on 7 July 2026, in San Diego. RNDP-001 is an off-the-shelf, allogeneic neuron replacement cell therapy designe</p>